Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | CSF1R | P07333 | 18/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.44 |
| ▸ | MET | P08581 | 5/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | KIT | P10721 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065407 | 0.77 | RAF1 (0.31) | — | |
| SCHEMBL574031 | 0.76 | KDR (0.59) | KDRCSF1RPDGFRBPDGFRAMET | |
| SCHEMBL573813 | 0.74 | KDR (0.59) | KDRCSF1RPDGFRBPDGFRAMET | |
| SCHEMBL31352505 | 0.74 | CSF1R (0.54) | KDRCSF1RPDGFRBPDGFRAMET | |
| SCHEMBL5062318 | 0.73 | KDR (0.41) | KDRCSF1RPDGFRBPDGFRAMET | |
| SCHEMBL27866390 | 0.73 | CSF1R (0.50) | KDRCSF1RPDGFRBPDGFRAMET | |
| SCHEMBL573785 | 0.73 | CSF1R (0.66) | KDRCSF1RPDGFRBPDGFRAMET | |
| SCHEMBL2919897 | 0.72 | AXL (0.60) | KDRCSF1RPDGFRBPDGFRAMET | |
| SCHEMBL828028 | 0.72 | CSF1R (0.46) | KDRCSF1RPDGFRBPDGFRAMET | |
| SCHEMBL2448639 | 0.72 | CSF1R (0.44) | KDRCSF1RPDGFRBPDGFRAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | KDR 239/4885CSF1R 197/4885PDGFRB 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.